Key facts
- Brink Therapeutics’s last known valuation is $12.1M (Apr 2025).
- It has raised $3.8M; the latest was Seed Round ($3.8M) in Apr 2025.
- Notable investors include Plug and Play Tech Center, Kima Ventures, Agoranov, Kurma Partners, Breega — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Brink Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Brink Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Brink Therapeutics
Developer of an advanced gene editing technology designed for in vivo cell and gene therapy. The company's technology uses a miniaturized system that mimics natural selection in the lab to improve proteins over successive cycles and accelerates how quickly recombinases can be tested and optimized, enabling biomedical researchers and therapeutic developers to create cell and gene therapies for cancer, inherited conditions, and other complex diseases with improved efficiency and control.
- Sector
- Healthcare
- HQ
- Paris, France
- Founded
- 2024
- Employees
- 2
- Website
- brinktx.com/
- Ownership
- Privately Held (backing)
Brink Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Brink Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Brink Therapeutics in its N-PORT filings yet. We sweep new filings monthly.